# Eli Lilly and Company Type: Company (LLY) Source: GetYourBrief — https://getyourbrief.com/entity/eli-lilly-and-company Canonical HTML page: https://getyourbrief.com/entity/eli-lilly-and-company ## Timeline - **2027-Q1**: Expected FDA submission — Lilly plans to file retatrutide for FDA approval. - **2026-08-03**: Early access program announced — Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval. - **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act. - **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act. - **2026-07-01**: 80-week trial results released — Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease. - **2026-06**: Off-Label Drug Mandate — The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process. - **2026-06**: Off-Label Drug Mandate — The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process. - **2026-05-05**: Publication of Articles — Two sources publish analyses on reasons to buy Eli Lilly stock, highlighting recent performance and future prospects - **2026-05**: Vida Health Assessment — Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse. - **2026-05**: Vida Health Assessment — Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse. - **2026-03-13**: Impurity Warning — Lilly issues formal warning after testing reveals impurities in compounded samples. - **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss. - **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss. - **2026-02**: Employer Imposes Vida Health Requirement — Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits. - **2026-02**: Employer Imposes Vida Health Requirement — Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits. ## Recent coverage (14 stories, network-wide) ### Eli Lilly’s retatrutide EAP: access for patients with 2+ severe comorbidities 2026-08-05 10:24:43 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence. Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-expanded-access-obesity-drug-2026 ### Wegovy 7.2 mg Shows 19% Weight Loss; Novo Sues Lilly Over Patient Misinformation 2026-07-21 14:14:59 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 3 The suit ensures obesity patients receive the latest efficacy data, as Novo contends Lilly’s ads deny consumers a full picture of treatment options, potentially swaying prescriptions. Full story: https://gethealthbrief.com/story/novo-lilly-glp1-lawsuit-patient-data ### STEP UP Trial’s 19% Weight Loss Underpins Novo’s Suit Against Lilly’s GLP-1 Ads 2026-07-21 14:14:48 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 3 The litigation underscores the GLP-1 dosing race: Wegovy 7.2 mg’s clinical superiority reshapes head-to-head comparisons, forcing Lilly to legally defend its ad strategy amid rapid innovation. Full story: https://getbiobrief.com/story/novo-lilly-glp1-lawsuit-stepup-clinical-data ### Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction 2026-07-21 14:14:08 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 3 Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma. Full story: https://getlegalbrief.com/story/novo-sues-lilly-false-advertising-glp1-injunction ### Eli Lilly’s Rs 2.15 lakh cancer pill enters India: Will precision oncology widen the equity gap? 2026-06-26 01:54:12 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2 Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system. Full story: https://gethealthbrief.com/story/tanstrive-india-launch-access-cost ### Vida Health's 2-Drug Mandate Before $1,000/Month Zepbound Sparks Regulatory Risk 2026-06-14 21:09:45 · Sector: startups · Sentiment: Negative · Impact: 6/10 · Sources: 7 Startup Vida Health’s cost-control strategy—forcing patients to try two off-label generics before covering pricey GLP-1s—is drawing backlash from doctors and could invite regulatory scrutiny, threatening the obesity telehealth sector. Full story: https://getstartupbrief.com/story/vida-health-regulatory-risk ### Telehealth Gatekeepers Block 57-Year-Old’s GLP-1 Prescription, Sparking Doctor Alarm 2026-06-14 21:07:57 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 7 A California man’s employer-mandated use of Vida Health stalled his Zepbound treatment for obstructive sleep apnea, highlighting how telehealth platforms are overriding primary care physicians to reduce obesity drug costs. Full story: https://gethealthbrief.com/story/telehealth-glp-1-gatekeeping ### Eli Lilly Shares Gain 25%: Key Investment Drivers 2026-05-05 02:37:07 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2 With Eli Lilly's stock up 25% year-to-date, investors are eyeing its strong financials and market position amid pharma sector growth. This development signals potential for high returns in finance circles, influenced by earnings and economic factors. Regulatory and market dynamics could shape future investment strategies in stocks like LLY. Full story: https://getfinancebrief.com/story/eli-lilly-finance-investment ### Eli Lilly Stock Up 25% YTD: Biotech Breakthroughs Drive Growth 2026-05-05 02:36:33 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine. Full story: https://getbiobrief.com/story/eli-lilly-biotech-opportunities ### Lilly Flags Impurities in Compounded GLP-1s, Escalating Regulatory Battle 2026-03-13 20:18:29 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 23 Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement. Full story: https://getlegalbrief.com/story/lilly-tirzepatide-compounding-impurity-warning ### REX Shares Announces Monthly Dividends Across Crypto-Adjacent ETF Suite 2026-03-03 08:59:31 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 6 REX Shares has declared monthly dividend distributions for its Growth & Income ETF lineup, including key crypto-linked products tracking Coinbase and MicroStrategy. These payouts reflect the ongoing trend of utilizing high-volatility technology and digital asset proxies to generate consistent yield for income-focused investors. Full story: https://getcryptobrief.com/story/rex-shares-etf-dividends-march-2026 ### Fisher Asset Management Boosts Eli Lilly Stake Amid GLP-1 Growth 2026-03-03 00:59:15 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Fisher Asset Management has increased its position in Eli Lilly and Company by 3.5%, bringing its total holdings to over 4.4 million shares. This institutional accumulation underscores continued confidence in Lilly's market-leading metabolic health portfolio and long-term pharmaceutical dominance. Full story: https://getfinancebrief.com/story/fisher-asset-management-increases-eli-lilly-stake ### Fisher Asset Management Increases Eli Lilly Stake to 4.45M Shares 2026-03-03 00:58:42 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Fisher Asset Management LLC expanded its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. This move brings the firm's total holdings to approximately 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory. Full story: https://getbiobrief.com/story/fisher-asset-management-increases-eli-lilly-stake-q3-2026 ### Fisher Asset Management Boosts Eli Lilly Stake Amid GLP-1 Expansion 2026-03-03 00:58:10 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory. Full story: https://gethealthbrief.com/story/fisher-asset-management-eli-lilly-stake-increase --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.